# US 2003/0223997 A1 · Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223997 A1
- Document ID: US20030223997A1
- Status: Published application
- Kind: A1
- Application number: 10/087,190
- Filed: 2002-02-28
- Published: 2003-12-04
- Earliest claimed: 2001-02-08
- Assignees: Agensys, Inc.
- Inventors: Pia M. Challita-Eid; Rene S. Hubert; Arthur B. Raitano; Mary Faris; Daniel E. H. Afar; Wangmao Ge; Aya Jakobovits
- Web page: https://patentgrep.com/patent/US20030223997A1

## CPC

- C07K 14/47: from mammals
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- C07K 16/30: from tumour cells
- G01N 33/575: for cancer
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A novel gene (designated 121P1F1) and its encoded protein, and variants thereof, are described wherein 121P1F1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P1F1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P1F1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P1F1 can be used in active or passive immunization.

## Claims

### Claim 1

A composition comprising:
a substance that modulates the status of 121P1F1, or a molecule that is modulated by 121P1F1 whereby the status of a cell that expresses 121P1F1 is modulated:

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A pharmaceutical composition that comprises the composition of claim 1 in a human unit dose form.

### Claim 4 (depends on 1)

A composition of claim 1 wherein the substance comprises an antibody or fragment thereof that specifically binds to a 121P1F1-related protein.

### Claim 5 (depends on 4)

The antibody or fragment thereof of claim 4, which is monoclonal.

### Claim 6 (depends on 5)

A recombinant protein comprising an antigen-binding region of a monoclonal antibody of claim 5.

### Claim 7 (depends on 4)

The antibody or fragment thereof of claim 4, which is labeled with a detectable marker.

### Claim 8 (depends on 6)

The recombinant protein of claim 6, which is labeled with a detectable marker.

### Claim 9 (depends on 4)

The antibody fragment of an antibody of claim 4, which is an Fab, F(ab′)2, Fv or sFv fragment.

### Claim 10 (depends on 4)

The antibody of claim 4, which is a human antibody, a humanized antibody or a chimeric antibody.

### Claim 11 (depends on 4)

A non-human transgenic animal that produces an antibody of claim 4.

### Claim 12 (depends on 5)

A hybridoma that produces an antibody of claim 5.

### Claim 13 (depends on 5)

A single chain monoclonal antibody that immunospecifically binds to a 121P1F1-related protein, and that comprises the variable domains of the heavy and light chains of a monoclonal antibody of claim 5.

### Claim 14 (depends on 13)

A vector comprising a polynucleotide that encodes a single chain monoclonal antibody of claim 13.

### Claim 15 (depends on 4)

A method of delivering a cytotoxic agent or a diagnostic agent to a cell that expresses 121P1F1. said method comprising:
providing the cytotoxic agent or the diagnostic agent conjugated to an antibody or fragment thereof of claim 4; and,
exposing the cell to the antibody-agent or fragment-agent conjugate.

### Claim 16 (depends on 1)

A composition of claim 1 wherein the substance comprises a polynucleotide that encodes an antibody or fragment thereof either of which immunospecifically binds to an 121P1F1-related protein.

### Claim 17 (depends on 3)

A composition of claim 3 wherein the substance comprises a 121P1F1-related protein.

### Claim 18 (depends on 17)

The composition of claim 17, further comprising antigen presenting cells.

### Claim 19 (depends on 1)

The composition of claim 1 wherein the substance comprises an analog of a peptide of eight, nine, ten, or eleven contiguous amino acids of FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, or FIG. 2F (SEQ ID NO: ______).

### Claim 20 (depends on 1)

A composition of claim 1 wherein the substance comprises a CTL polypeptide epitope of the amino acid sequence of FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, or FIG. 2F (SEQ ID NO: ______), with a proviso that the epitope is not the entire amino acid sequence of FIG. 2A (SEQ ID NO: ______).

### Claim 21 (depends on 20)

The composition of claim 20 wherein the CTL epitope comprises a polypeptide selected from Tables V-XVIII, XXVI, and XXVII, with a proviso that the epitope is not the entire amino acid sequence of FIG. 2A (SEQ ID NO: ______).

### Claim 22 (depends on 1)

A composition of claim 1 wherein the substance comprises an antibody polypeptide epitope of the amino acid sequence of FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, or FIG. 2F (SEQ ID NO: ______), with a proviso that the epitope is not the entire amino acid sequence of FIG. 2A (SEQ ID NO: ______).

### Claim 23 (depends on 22)

A composition of claim 22 wherein the antibody epitope comprises a peptide region of at least 5 amino acids of FIG. 2A (SEQ ID NO: L in any whole number increment up to 205 that includes an amino acid position selected from: an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5A, an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6A, an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7A: an amino acid position having a value greater than 0.5 in the Average Flexibility profile on FIG. 8A; or an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9A. with a proviso that the epitope is not the entire amino acid sequence of FIG. 2A (SEQ ID NO: ______).

### Claim 24 (depends on 23)

The recombinant protein of claim 23, which comprises murine antigen binding region residues and human constant region residues.

### Claim 25 (depends on 19)

A polynucleotide that encodes an analog peptide of claim 19.

### Claim 26 (depends on 1)

A composition of claim 1 wherein the substance comprises a polynucleotide that comprises an 121P1F1-related protein coding sequence, with a Droviso that the coding sequence does not encode the entire amino acid sequence of FIG. 2A (SEQ ID NO: ______).

### Claim 27 (depends on 26)

The composition of claim 26 in human unit dose form.

### Claim 28 (depends on 26)

A composition of claim 26 comprising a polynucleotide from position number 82 through number 696 of FIG. 2A (SEQ ID NO: ______) followed by a stop codon.

### Claim 29 (depends on 28)

The composition of claim 28 wherein T is substituted with U.

### Claim 30 (depends on 32)

A composition of claim 32 that comprises the coding sequence for the polynucleotide of FIG. 2A (SEQ ID NO: ______).

### Claim 31 (depends on 30)

The composition of claim 30 wherein T is substituted with U.

### Claim 32 (depends on 26)

A composition of claim 26 comprising a polynucleotide that encodes an 121P1F1-related protein that is at least 90% homologous to the entire amino acid sequence shown in FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, or FIG. 2F (SEQ ID NO: ______).

### Claim 33 (depends on 32)

The composition of claim 32 wherein the polynucleotide encodes an 121P1F1-related protein that is at least 90% identical to the entire amino acid sequence shown in FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, or FIG. 2F (SEQ ID NO: ______).

### Claim 34 (depends on 26)

A composition of claim 26 wherein the substance comprises a polynucleotide that encodes at least one peptide set forth in Tables V-XVIII, XXVI. and XXVII, with a proviso that the entire amino acid sequence of FIG. 2A is not encoded.

### Claim 35 (depends on 26)

A composition of claim 26 comprising a polynucleotide that encodes a peptide region of at least 5 amino acids of FIG. 2A (SEQ ID NO: ______) that includes an amino acid position selected from: an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5A, an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6A; an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7A; an amino acid position having a value greater than 0.5 in the Average Flexibility profile on FIG. 8A; or an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9A, with a proviso that the entire amino acid sequence of FIG. 2A (SEQ ID NO: ______) is not encoded.

### Claim 36 (depends on 26)

A composition comprising a polynucleotide that is filly complementary to a polynucleotide of claim 26.

### Claim 37 (depends on 28)

A composition comprising a polynucleotide that is filly complementary to a polynucleotide of claim 28.

### Claim 38 (depends on 29)

A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 29.

### Claim 39 (depends on 30)

A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 30, in human unit dose form.

### Claim 40 (depends on 31)

A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 31.

### Claim 41 (depends on 32)

A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 32.

### Claim 42 (depends on 33)

A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 33.

### Claim 43 (depends on 34)

A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 34.

### Claim 44 (depends on 1)

A pharmaceutical composition of claim 1 wherein the substance comprises a ribozyme that cleaves a polynucleotide having 121P1F1 coding sequence and a physiologically acceptable carrier.

### Claim 45 (depends on 1)

A pharmaceutical composition of claim 1 wherein the substance comprises a nucleic acid molecule that encodes a ribozyme that cleaves a polynucleotide having 121P1F1 coding sequence and a physiologically acceptable carrier.

### Claim 46 (depends on 1)

A pharmaceutical composition of claim 1 wherein the substance comprises human T cells, wherein said T cells specifically recognize a 121P1F1 peptide sequence in the context of a particular HLA molecule.

### Claim 47 (depends on 1)

A method of inhibiting growth of cancer cells that expresses 121P1F1, the method comprising:
administering to the cells the composition of claim 1.

### Claim 48 (depends on 47)

A method of claim 47 of inhibiting growth of cancer cells that express 121P1F1, the method comprising steps of:
administering to said cells an antibody or fragment thereof either of which specifically bind to a 121P1F1-related protein.

### Claim 49 (depends on 47)

A method of claim 47 of inhibiting growth of cancer cells that express 121P1F1, the method comprising steps of:
administering to said cells a vector that encodes a single chain monoclonal antibody that immunospecifically binds to an 121P1F1-related protein.

### Claim 50 (depends on 47)

A method of claim 47 of inhibiting growth of cancer cells that express 121P1F1, the method comprising steps of:
administering to said cells an 121P1F1-related protein.

### Claim 51 (depends on 47)

A method of claim 47 of inhibiting growth of cancer cells that express 121P1F1, the method comprising steps of:
administering to said cells a vector that comprises a polynucleotide comprising a 121P1F1-related protein coding sequence.

### Claim 52 (depends on 47)

A method of claim 47 of inhibiting growth of cancer cells that express 121P1F1, the method comprising steps of:
administering to said cells an antisense polynucleotide complementary to a polynucleotide having a 121P1F1 coding bi sequence.

### Claim 53 (depends on 47)

A method of claim 47 of inhibiting growth of cancer cells that express 121P1F1, the method comprising steps of:
administering to said cells a ribozyme that cleaves a polynucleotide having 121P1F1 coding sequence.

### Claim 54 (depends on 47)

A method of claim 47 of inhibiting growth of cancer cells that express 121P1F1 and a particular HLA molecule, the method comprising steps of:
administering to said cells human T cells, wherein said T cells specifically recognize an 121P1F1 peptide sequence in the context of the particular HLA molecule.

### Claim 55 (depends on 1)

A method of treating a patient who bears cancer cells that express 121P1F1. the method comprising:
administering to the patient the composition of claim 1.

### Claim 56 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that expresses 121P1F1 the method comprising steps of:
administering to said patient an antibody or fragment thereof either of which specifically binds to a 121P1F1-related protein.

### Claim 57 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that expresses 121P1F1, the method comprising steps of:
administering to said patient a vector that encodes an antibody or fragment thereof either of which immunospecifically bind to an 121P1F1-related protein.

### Claim 58 (depends on 57)

A method of claim 57 for treating a patient with a cancer that expresses 121P1F1, the method comprising steps of:
administering to said patient a vector that delivers a single chain monoclonal antibody coding sequence, whereby the encoded single chain antibody is expressed intracellularly within cancer cells that express 121P1F1.

### Claim 59 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that express 121P1F1, the method comprising steps of:
administering to said patient an 121P1F1-related protein.

### Claim 60 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that express 121P1F1, the method comprising steps of:
administering to said patient a vector that comprises a polynucleotide comprising a 121P1F1-related protein coding sequence.

### Claim 61 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that express 121P1F1, the method comprising steps of:
administering to said patient an antisense polynucleotide complementary to a polynucleotide having a 121P1F1 coding sequence.

### Claim 62 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that express 121P1F1, the method comprising steps of:
administering to said patient a ribozyme that cleaves a polynucleotide having an 121P1F1 coding sequence.

### Claim 63 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that express 121P1F1, the method comprising steps of:
administering to said patient a nucleic acid molecule that encodes a ribozyme that cleaves a polynucleotide having an 121P1F1 coding sequence.

### Claim 64 (depends on 55)

A method of claim 55 for treating a patient who bears cancer cells that express 121P1F1 and a particular HLA molecule, the method comprising steps of:
administering to said patient human T cells, wherein said T cells specifically recognize an 121P1F1 peptide sequence in the context of the particular HLA molecule.

### Claim 65

A method of generating a mammalian immune response directed to 121P1F1, the method comprising:
exposing cells of the mammal's immune system to an immunogenic portion of
a) an 121P1F1-related protein and/or
b) a nucleotide sequence that encodes said protein,
whereby an immune response is generated to 121P1F1.

### Claim 66 (depends on 65)

A method of inducing an immune response of claim 65, said method comprising:
providing a 121P1F1-related protein that comprises at least one T cell or at least one B cell epitope;
contacting the epitope with a mammalian immune system T cell or B cell respectively, whereby the T cell or B cell is induced.

### Claim 67 (depends on 66)

The method of claim 66 wherein the immune system cell is a B cell, whereby the induced B cell generates antibodies that specifically bind to the 121P1F1-related protein.

### Claim 68 (depends on 66)

The method of claim 66 wherein the immune system cell is a T cell that is a cytotoxic T cell (CTL), whereby the activated CTL kills an autologous cell that expresses the 121P1F1-related protein.

### Claim 69 (depends on 66)

The method of claim 66 wherein the immune system cell is a T cell that is a helper T cell (HTL), whereby the activated HTL secretes cytokines that facilitate the cytotoxic activity of a cytotoxic T cell (CTL) or the antibody producing activity of a B cell.

### Claim 70 (depends on 1)

An assay for detecting the presence of a 121P1F1-related protein or polynucleotide in a biological sample from a patient who has or who is suspected of having cancer, comprising steps of:
contacting the sample with a substance of claim 1 that specifically binds to the 121P1F1-related protein or polynucleotide, respectively; and,
determining that there is a complex of the substance and 121P1F1-related protein or the substance and 121P1F1-related polynucleotide, respectively.

### Claim 71 (depends on 70)

An assay of claim 70 for detecting the presence of a 121P1F1-related protein in a biological sample from a patient who has or who is suspected of having cancer, comprising steps of:
contacting the sample with an antibody or fragment thereof either of which specifically bind to the 121P1F1-related protein; and,
determining that there is a complex of the antibody or fragment thereof and 121P1F1-related protein.

### Claim 72 (depends on 70)

The assay in accordance with claim 70 further comprising a step of:
taking a sample from a patient who has or who is suspected of having cancer.

### Claim 73 (depends on 70)

The assay of claim 70 for detecting the presence of an 121P1F1 polynucleotide in a biological sample, comprising:
contacting the sample with a polynucleotide probe that specifically hybridizes to the polynucleotide of FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, or FIG. 2F (SEQ ID NO: ______); and,
detecting the presence of a hybridization complex formed by the hybridization of the probe with 121P1F1 polynucleotide in the sample, wherein the presence of the hybridization complex indicates the presence of 121P1F1 polynucleotide within the sample.

### Claim 74 (depends on 70)

An assay in accordance with claim 70 for detecting the presence of 121P1F1 mRNA in a biological sample from a patient who has or who is suspected of having cancer, said method comprising:
producing cDNA from the sample by reverse transcription using at least one primer;
amplifying the cDNA so produced using 121P1F1 polynucleotides as sense and antisense primers, wherein the 121P1F1 polynucleotides used as the sense and antisense primers are capable of amplifying 121P1F1 cDNA; and
detecting the presence of the amplified 121P1F1 cDNA.

### Claim 75

A method for monitoring 121P1F1 gene products in a biological sample from a patient who has or who is suspected of having cancer, the method comprising:
determining the status of 121P1F1 gene products expressed by cells in a tissue sample from an individual;
comparing the status so determined to the status of 121P1F1 gene products in a corresponding normal sample; and,
identifying the presence of aberrant 121P1F1 gene products in the sample relative to the normal sample.

### Claim 76 (depends on 75)

A method of monitoring the presence of cancer in an individual comprising: performing the method of claim 75 whereby the presence of elevated gene products 121P1F1 mRNA or 121P1F1 protein in the test sample relative to the normal tissue sample indicates the presence or status of a cancer.

### Claim 77 (depends on 76)

The method of claim 76 wherein the cancer occurs in a tissue set forth in Table I.
